1
项与 CAR20.19.22 T-cells(Miltenyi Biomedicine GmbH) 相关的临床试验Phase I Trial of Anti-CD20, Anti-CD19, Anti-CD22 CAR (CAR20.19.22) T-cells for Relapsed, Refractory B-cell Malignancies
In this phase I study, the investigators will first evaluate the safety of CAR20.19.22 T-cells in patients with B-cell non-Hodgkin lymphoma (NHL) / chronic lymphocytic leukemia (CLL).
100 项与 CAR20.19.22 T-cells(Miltenyi Biomedicine GmbH) 相关的临床结果
100 项与 CAR20.19.22 T-cells(Miltenyi Biomedicine GmbH) 相关的转化医学
100 项与 CAR20.19.22 T-cells(Miltenyi Biomedicine GmbH) 相关的专利(医药)
100 项与 CAR20.19.22 T-cells(Miltenyi Biomedicine GmbH) 相关的药物交易